Prostate Cancer
Prostate Cancer
Advertisement
Marc Greenstein, DOmCSPC | October 31, 2024
Dr. Greenstein shares insights on the overall survival benefit of apalutamide over enzalutamide in a recent real-world study.
View More
Brian Rini, MD, FASCOProstate Cancer | October 29, 2024
The panelists examine the existing data for T cell engagers in CRPC and how the data might affect clinical practice.
Brian Rini, MD, FASCOProstate Cancer | October 29, 2024
The panelists discuss T cell engagers, including an introduction and discussion of cytokine release syndrome.
Brian Rini, MD, FASCORLT | October 29, 2024
The panel discusses the emerging field of PSMA-targeted alpha radioligand therapy, with a focus on HK2.
Brian Rini, MD, FASCORLT | October 29, 2024
The panel discusses the results of PEACE-3, which evaluated enzalutamide with or without radium-223 for MCRPC.
Brian Rini, MD, FASCORLT | October 29, 2024
The panel discusses two significant trials in metastatic hormone-sensitive prostate cancer.
Leonard J. Appleman, MD, PhDProstate Cancer | October 30, 2024
The final segment of this roundtable series discusses radiopharmaceuticals and PARP inhibitors.
Leonard J. Appleman, MD, PhDProstate Cancer | October 30, 2024
Part five of this roundtable series covers data and insights from the ARANOTE and PEACE 3 trials.
Leonard J. Appleman, MD, PhDProstate Cancer | October 30, 2024
Part four of a PCa roundtable series focuses on the effectiveness of ADT with triplet therapy.
Brian Rini, MD, FASCORLT | October 25, 2024
Part 2 of the Radioligands session from Uromigos Live 2024 features a discussion on the SPLASH results from ESMO 2024.
Brian Rini, MD, FASCORLT | October 24, 2024
The first part of five segments from the Uromigos Live 2024 session on radioligands.
Laura LitwinProstate Cancer Diagnostics | October 23, 2024
18F rhPSMA-7.3 (rhPSMA) PET/MRI imaging is a potential "one-stop shop" for detecting biochemically recurrent prostate cancer.
Jordana JampelCRPC | October 11, 2024
The primary endpoint of rPFS was maintained in both cohorts.
Tanya Dorff, MDCRPC | October 10, 2024
Dr. Dorff shares highlights from Uromigos Live 2024 and talks about the role of ADT in prostate cancer treatment.
Geoffrey Johnson, MD, PhDProstate Cancer Diagnostics | October 10, 2024
The CLARIFY trial leveraged PSMA PET imaging for personalized prostate cancer treatment and detecting distant metastases.
Geoffrey Johnson, MD, PhDProstate Cancer Diagnostics | October 10, 2024
Advanced PSMA PET imaging improved surgical outcomes for patients with high-risk prostate cancer in the CLARIFY trial.
Emily MenendezRLT | October 9, 2024
Early phase I data on 177Lu rhPSMA-10.1 has demonstrated an encouraging safety profile for the novel radioligand therapy.
Pedro Barata, MDCRPC | October 2, 2024
In the final segment of our roundtable series, the panelists discuss the treatment of CRPC, focusing on metastatic disease.
Pedro Barata, MDCRPC | October 2, 2024
In the fifth segment of our roundtable series, the treatment of patients with CRPC is discussed.
Pedro Barata, MDProstate Cancer | October 2, 2024
In the fourth part of our series, the panelists discuss PROs and potential patient comorbidities.
Advertisement
Advertisement
Advertisement